CY1119750T1 - Παραλλαγες ανθρωπινου gdnf - Google Patents

Παραλλαγες ανθρωπινου gdnf

Info

Publication number
CY1119750T1
CY1119750T1 CY20181100021T CY181100021T CY1119750T1 CY 1119750 T1 CY1119750 T1 CY 1119750T1 CY 20181100021 T CY20181100021 T CY 20181100021T CY 181100021 T CY181100021 T CY 181100021T CY 1119750 T1 CY1119750 T1 CY 1119750T1
Authority
CY
Cyprus
Prior art keywords
human beings
gdnf
gdnf human
methods
relates
Prior art date
Application number
CY20181100021T
Other languages
English (en)
Inventor
Donmienne Doen Mun Leung
Jirong Lu
Kalpana Mahesh Merchant
Mahmoud Ghanem
Linda Maureen O'bryan
Rosamund Carol Smith
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1119750T1 publication Critical patent/CY1119750T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • External Artificial Organs (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε νέες παραλλαγές ανθρώπινου νευροτροφικού παράγοντα προερχόμενου από γλοιακά κύτταρα (GDNF) και μεθόδους για τη χρήση τους.
CY20181100021T 2011-04-11 2018-01-09 Παραλλαγες ανθρωπινου gdnf CY1119750T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (1)

Publication Number Publication Date
CY1119750T1 true CY1119750T1 (el) 2018-06-27

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100021T CY1119750T1 (el) 2011-04-11 2018-01-09 Παραλλαγες ανθρωπινου gdnf

Country Status (28)

Country Link
US (1) US9243046B2 (el)
EP (1) EP2696889B1 (el)
JP (1) JP6093345B2 (el)
KR (1) KR101554799B1 (el)
CN (1) CN103635201B (el)
AU (1) AU2012243178B2 (el)
BR (1) BR112013026004B1 (el)
CA (1) CA2833158C (el)
CY (1) CY1119750T1 (el)
DK (1) DK2696889T3 (el)
EA (1) EA025129B1 (el)
ES (1) ES2656020T3 (el)
HR (1) HRP20171993T1 (el)
HU (1) HUE036239T2 (el)
IL (1) IL228102A (el)
LT (1) LT2696889T (el)
ME (1) ME02849B (el)
MX (1) MX337206B (el)
NO (1) NO2696889T3 (el)
PL (1) PL2696889T3 (el)
PT (1) PT2696889T (el)
RS (1) RS56639B1 (el)
SG (1) SG193483A1 (el)
SI (1) SI2696889T1 (el)
TW (1) TWI583698B (el)
UA (1) UA112981C2 (el)
WO (1) WO2012141936A1 (el)
ZA (1) ZA201306556B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017263174A1 (en) 2016-05-13 2018-12-13 Instituto de Medicina Molecular João Lobo Antunes Methods of treating diseases associated with ILC3 cells
JP2023515915A (ja) * 2019-12-19 2023-04-17 トランスフェルト・プラス・ソシエテ・アン・コマンディテ 腸のニューロパチーを治療するためのグリア細胞株由来神経栄養因子（ｇｄｎｆ）の使用
CA3222177A1 (en) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100242093B1 (ko) 1991-09-20 2000-02-01 그레고리 아보트 신경교 유도 신경 영양성 인자
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
CA2751445C (en) * 2009-02-06 2018-06-19 Pepscan Systems B.V. Truncated cystine-knot proteins

Also Published As

Publication number Publication date
JP6093345B2 (ja) 2017-03-08
KR20130131470A (ko) 2013-12-03
AU2012243178B2 (en) 2016-09-29
BR112013026004B1 (pt) 2020-09-29
UA112981C2 (uk) 2016-11-25
EA201370204A1 (ru) 2014-02-28
SI2696889T1 (en) 2018-01-31
HUE036239T2 (hu) 2018-06-28
HRP20171993T1 (hr) 2018-02-09
NZ614325A (en) 2015-07-31
LT2696889T (lt) 2018-02-12
CN103635201A (zh) 2014-03-12
RS56639B1 (sr) 2018-03-30
WO2012141936A1 (en) 2012-10-18
CN103635201B (zh) 2016-11-09
US20130324474A1 (en) 2013-12-05
IL228102A (en) 2017-04-30
SG193483A1 (en) 2013-10-30
PT2696889T (pt) 2018-02-05
KR101554799B1 (ko) 2015-09-21
DK2696889T3 (en) 2018-01-22
AU2012243178A1 (en) 2013-09-05
TW201245220A (en) 2012-11-16
JP2014512369A (ja) 2014-05-22
ME02849B (me) 2018-01-20
TWI583698B (zh) 2017-05-21
ES2656020T3 (es) 2018-02-22
NO2696889T3 (el) 2018-04-14
EP2696889B1 (en) 2017-11-15
IL228102A0 (en) 2013-09-30
ZA201306556B (en) 2015-03-25
US9243046B2 (en) 2016-01-26
MX337206B (es) 2016-02-17
CA2833158C (en) 2018-07-17
EA025129B1 (ru) 2016-11-30
BR112013026004A2 (pt) 2016-11-29
EP2696889A1 (en) 2014-02-19
CA2833158A1 (en) 2012-10-18
PL2696889T3 (pl) 2018-04-30
MX2013011919A (es) 2014-03-27

Similar Documents

Publication Publication Date Title
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UY34254A (es) Proteínas y péptidos modificados.
UY34680A (es) Anticuerpos humanos anti-cd27, métodos, y usos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CY1119151T1 (el) Ν-(4-(αζαϊνδαζολ-6-υλ)-φαινυλ)-σουλφοναμιδiα και η χρηση τους ως φαρμακα
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
EA201201016A1 (ru) Антидоты антикоагулянтов
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
BR112014028334A2 (pt) derivados dipeptídicos de lisina ácido glutâmico.
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
BR112015012907A2 (pt) composição de cuidado pessoal
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.